SYMPOSIUM

ATHENS 7-9 MAY 2026

  • eadv.org
EADV Logo

EADV Symposium Abstracts

DEADLINE EXTENDED

SUBMIT BY 6 18 FEBRUARY 2025

The EADV Symposium provides a valuable platform to showcase your research globally, gaining visibility among key opinion leaders.

Submit your Abstract

Abstract submissions

Multiple abstracts are accepted and may be chosen for an oral free communication presentation or an ePoster, contributing to the extensive scientific programme. 

DEADLINE EXTENDED

  • Abstract submissions opening 2 December 2025
  • Abstract submissions closing  6  2 February 2026
  • Abstract evaluation notification   24 March 2026
Submit your Abstract
  • ePoster submissions opening 30 March 2026
  • ePoster submissions closing 30 April 2026

How to prepare and submit your abstract

To correctly submit your abstract, you must use and fill in the HTML fields available on the submission platform.
HTML fields for abstract body are divided by the submission system into the following fixed sections: 

    1. Introduction
    2. Materials and Methods
    3. Results
    4. Conclusion

Maximum one table/ image file (.jpg, .gif, .png, .bmp, .webp file) can be included as attachment to each of the above abstract sections. Please remember to directly include in the image file its title, description, footnotes, or other references as deemed necessary.

When submitting an abstract, the data of the author set as Presenting author must include a valid email contact. In case of abstract acceptance, this contact will be used, in case of abstract acceptance, to notify the instructions and requirements for the preparation of the ePoster/ oral presentation.

When submitting an abstract, you will be asked two important questions for internal monitoring purpose:

    1. Was your abstract presented/ published in previous occasions (being classifiable as “encore” abstract)?
    2. Are you submitting an abstract involving collaborations with Industry?

 

ADDITIONAL ABSTRACT REQUIREMENTS:

  • Abstracts must be submitted in English.
  • The abstract title should not be written entirely in capital letters.
  • The size of the abstract is limited to 4,000 characters (spaces included).
    Please note that the submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
  • Please be informed that the abstract title is free of character number limitation.
  • Tables and figures (graphs) are allowed, and they are not taken into consideration for the character count limit.
  • Pictures of patients and body parts are NOT allowed for inclusion in the abstract body. Abstract containing these kinds of pictures will be rejected.
  • No identifying features such as names of hospitals, medical schools, clinics, or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
  • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
  • Use generic names. The use of commercial drug names, brands and registered trademarks is strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
  • No mention of pharmaceutical company names should be included in the abstract.

During submission, you will be asked on whether your abstract should be preferentially considered for:

  • ePoster (digital-only, to be displayed during the event and on-demand)
  • Oral presentation (requires live attendance and oral speech from the presenting author)

If an abstract is submitted with preference for an “Oral presentation”, after the review process, the abstract submitter will be notified on one of the following possible outcomes:

  • If the submitter receives an acceptance confirmation with details for an oral presentation, this means that your abstract was accepted according to your preference.
  • If the submitter receives an ePoster acceptance confirmation, this means that, even though the abstract was not selected for an oral presentation, it is given the opportunity to be displayed as an ePoster.

If the submitter receives a rejection confirmation, this means that the final score of the submission did not reach the minimum acceptance threshold. In this case, authors are not entitled neither to submit an oral presentation, nor an ePoster

  • Abstracts must be submitted in English. A “blind” selection process will be used.
  • No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
  • The title should not be written entirely in capital letters.
  • The size of the abstract is limited to 3,000 characters.
  • The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
  • Tables and figures (graphs) are allowed and they are not taken into consideration for the character count. On the other hand, pictures of patients and body parts are NOT allowed. Abstract containing pictures will be rejected.
  • In order to be able to submit your abstract you must use the template downloadable on the submission platform.
  • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
  • Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
  • No mention of pharmaceutical company names should be included in the abstract.

The authors should specify if they prefer their submission to be considered for:

  • ePoster presentation only
  • Oral presentation only

If you submit your abstract as “Oral presentation” and it does not get selected for one of the Free Communication sessions, you will still have the possibility to submit an e-poster (if the abstract is considered above the threshold of acceptance by the reviewers).

Submit your Abstract

Evaluation and scoring

The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:

  • Is the content interesting, informative, novel or important?
  • Are the methods valid, the results relevant and the conclusions justified by the data?
  • Is the data presented with clarity and with appropriate structure?
  • Is the text written according to proper English grammar and syntactic style?

Copyright and publication of abstracts

Submission of an abstract implies that it has been approved by all listed authors.

The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation.

As part of the submission, the author grants EADV the exclusive right to first publish the abstract, and thereafter a non-exclusive right to publish, reproduce, distribute, display and store the abstract worldwide in all forms (including on the EADV website), formats and media now known or as developed in the future, including print, electronic and digital forms. For the avoidance of doubt, “electronic and digital forms” shall include but shall not be limited to databases, USB and forms accessible via electronic and digital networks, wireless transmission and communication systems. The author also grants EADV the exclusive right to retain income resulting from the above-mentioned publications by EADV. No fee shall be paid to the author by EADV for the license granted herein. The author will retain copyright of his or her abstract, including the pertaining moral rights. However, the author shall only reuse, reproduce or post the abstract with acknowledgment to the initial and first publication or presentation at an EADV event, and therefore reference the name of the EADV event and the date.

The License of Copyright Use between EADV and the author is governed and construed in accordance with the laws of Switzerland.

Accepted abstracts will be published here.

EADV Symposium - Media & Embargo Policy

Please see the below extract from the Symposium 2025 Media & Embargo Policy:
Every abstract author and meeting attendee, whether from the media, companies, institutions, organisations, universities, investment advisors, or any other category, must adhere to the embargo policy.

Embargoed materials include – but are not limited to – original journal articles, abstracts submitted to the EADV Events, abstracts from scientific meetings, written news releases, audio news releases, video news releases, interviews, slides, and any other materials associated with the scientific information being presented or published.

Embargoed materials, as well as results and information related to sessions at any meeting or event organised by EADV, are strictly confidential and cannot be disclosed in any manner or for any purpose before the lifting of the embargo by EADV.

Breaking an EADV embargo by any author, media outlet, press representative, member of staff or any third party acting on behalf of and/or under the authority of any media outlet or press representative is a contractual breach. The person/entity who released the information (i.e. the press representative who wrote the story/conducted the interview, etc.) will be held accountable and subjected to the penalties.

Prior publication

If the abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the embargo policy. If publication occurs online or in print before the specific embargo date and time set by the EADV, the abstract must be withdrawn or presented as an encore. Please notify the EADV via email at [email protected].

Embargo date and time for 2026 Symposium are not available yet

All abstracts:

The embargo is lifted at 11:00 CEST on 22 May 2025. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Industry abstracts:

The embargo is lifted at 11:00 CEST on 22 May 2025. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Before this date, only top-line content (no results or data) can be disclosed to announce the session content, learning outcomes and speakers.

FAQs

There are no costs for abstract submission.

The submitter does not need to be registered to the event

The submitter does not have to be an author of the abstract being submitted.

Yes. There is no limit to the number of abstracts that one can submit.

The submitter, and email address used by the submitter, will receive the notification.

It is not necessary for the presenting author to be the first author. Anyone from the authors list can present the abstract.

Yes, the presenting author act as a presenter for multiple abstracts

There is no limit to the number of authors on an abstract.

There are no word or character limits for the abstract title.

Yes, encores and/or adaptations are permitted.

Yes, QR codes are permitted on posters.

The content of the abstracts accepted as e-posters will be under embargo until the first day of the EADV event. Content of abstracts accepted as oral presentations will be under embargo until the date and time of the presentation of the abstract.

This does not apply to encores.

Click here to read the full Embargo Policy.

Abstracts can be withdrawn until 4 weeks before the event, i.e. Thursday, April 9, 2026.

Only the author set as presenting author during submission will be entitled to upload the ePoster/ oral presentation and will receive the necessary instructions.

Healthcare Professional definition

  1. Important note to Healthcare and Non-Healthcare Professionals
    Access to the different areas and sessions of the Symposium depends on the Healthcare Professional status.

    As a multidisciplinary audience will attend the EADV Symposium, the EADV will assign different classes to Healthcare Professionals (HCPs) and Non-Healthcare Professionals (non-HCPs) to ensure compliance with the AIFP (Asociace inovativního farmaceutického průmyslu v České republice) Code of Practice.
    Please read the description below to ensure that you (or your delegates) comply with the regulations in place.

EADV members are not automatically considered Healthcare Professionals

Please select the correct status (HCP or non-HCP) during registration.

  1. Definition
    The AIFP code defines Healthcare Professionals as follows:
    “any natural person that is a member of the medical, dental, pharmacy, or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe.
    For the purpose of AIFP Code, the definition of HCPs includes: any official or state employee, agency or other organization (whether in the public or private sector) that may prescribe, purchase, supply, recommend or administer Medicinal Products and any employee of a Member Company whose primary occupation is that of a practicing HCP, but excludes all other employees of a Member Company and a wholesaler or distributor of Medicinal Products.”

    Medical students     are not considered Healthcare Professionals under the current guidelines and will be automatically classified as Non-Healthcare Professionals.
  1. Industry sessions
    Satellite Symposia presenting data on the development, research, or other issues related to prescription medicine is restricted to Healthcare Professionals and Industry Participants as indicated by the Industry Session Organizer.
    All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs.

    Industry Session organisers can limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to achieving the session’s intended purpose. The organising company reserves the right to refuse single categories, particularly if they are not adequately related to the session’s objective and purpose.

    The industry session organiser is responsible for compliance with the session.